Decision Against Attorney Fees In Mucinex Patent Claim Could Resonate
Executive Summary
US federal court judge says Mucinex marketer Reckitt Benckiser is not responsible for OTC private label competitor Aurobindo’s attorney fees because its patent infringement complaint was not “exceptional” and its argument had merit. The decision could bolster drug firms' confidence in defending their patents.
You may also be interested in...
Reckitt Negotiating Details For Generic Mucinex It Will Provide Mutual
Litigation over supply agreement stayed after firms indicated to US district court they would settle. Mutual showed that RB failed to honor an agreement to supply generics of the original Mucinex guaifenesin, but had not provided sufficient detail for RB to provide a product that would meet regulatory standards.
Reckitt Negotiating Details For Generic Mucinex It Will Provide Mutual
Litigation over supply agreement stayed after firms indicated to US district court they would settle. Mutual showed that RB failed to honor an agreement to supply generics of the original Mucinex guaifenesin, but had not provided sufficient detail for RB to provide a product that would meet regulatory standards.
Perrigo Sets Generic Mucinex Launch After Patent Claim Decision
The private labeler clears a Reckitt Benckiser legal hurdle and will launch generic Mucinex (guaifenesin) by April. Watson has filed ANDAs for three Mucinex products and could be a good strategic partner for Perrigo, an analyst suggests.